Tatsuya Ide

Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan

Haruhiko Yoshida, Yasushi Shiratori, Mitsuhiko Moriyama et al. · Annals of Internal Medicine · 1999 · 1.1K citations

Medicine, Oncology, Cancer Control +16

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

Takumi Kawaguchi, Takafumi Yoshida, Masaru Harada et al. · American Journal Of Pathology · 2004 · 536 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +8

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Masashi Mizokami, Osamu Yokosuka, Tetsuo Takehara et al. · The Lancet Infectious Diseases · 2015 · 362 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Clearance of HCV Improves Insulin Resistance, Beta-Cell Function, and Hepatic Expression of Insulin Receptor Substrate 1 and 2

Takumi Kawaguchi, Tatsuya Ide, Eitaro Taniguchi et al. · The American Journal of Gastroenterology · 2007 · 252 citations

Medicine, Endocrinology, Infectious Diseases +17

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 <scp>HCV</scp> infection: an open‐label, phase 3 trial

Masao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno et al. · Journal of Viral Hepatitis · 2014 · 202 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17